We are developing new cell-based regenerative therapies.
We use adult and induced pluripotent stem cells (iPSC), regenerative factors (human platelet lysate, hPL) and extracellular vesicles (EV) for effective regenerative cell-based therapy approaches.
Projects
Projects
Research focus areas
Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes
Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes
Horizon EU
Heal
2022 - 2026
Broken Hearts
Deep Immune-Phenotyping of HLA-homozygous iPS-Cardiomyocytes
Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis
Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis
Horizon EU
Proto
2023 - 2027
Broken Bones
Mode of action & molecular mechanism of regenerative cell therapy in osteoarthritis
Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona
Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona
Horizon EU
Nexgen
2023 - 2027
EV Biomakers
Discovery of theranostic EV-based biomarkers of Parkinsons vaccination efficiency - Role of EV corona
CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation
CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation
CAR-NK-EV
CCS3
2024 - 2026
CAR-EV Biomarkers
Role of CAR-NK-derived EVs in leukemia cell lysis and immunomodulation
WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.
WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.
WISS25
GoodFibration
2024 - 2027
Scar-free Regeneration
Advancing scalable iPSC heart therapies for treating heart failure.
COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.
COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.
COST EU
Haplo.iPS
2022 - 2026
Universal Transplants
Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.
Publications
Publications
Adv Healthc Mater
2024
Advances in Extracellular Vesicle Research Over the Past Decade: Source and Isolation Method are Connected with Cargo and Function
Rodolphe Poupardin et al.
Adv Healthc Mater
2024
Advances in Extracellular Vesicle Research Over the Past Decade: Source and Isolation Method are Connected with Cargo and Function
Rodolphe Poupardin et al.
Adv Healthc Mater
2024
Advances in Extracellular Vesicle Research Over the Past Decade: Source and Isolation Method are Connected with Cargo and Function
Rodolphe Poupardin et al.
J Extracell Vesicles
2024
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Joshua A. Welsh et al.
J Extracell Vesicles
2024
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Joshua A. Welsh et al.
J Extracell Vesicles
2024
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Joshua A. Welsh et al.
Science TM
2023
The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells
Sarah Hochmann et al.
Science TM
2023
The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells
Sarah Hochmann et al.
Science TM
2023
The enhancer landscape predetermines the skeletal regeneration capacity of stromal cells
Sarah Hochmann et al.
